21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
Related Articles
Data Show Continued Benefit With Frontline Asciminib in Ph+ CML-CP
Asciminib continued to improve outcomes when compared to investigator-selected TKIs in patients with newly diagnosed, Ph+ CML-CP in the ASC4FIRST trial.
What’s a calorie deficit?
A calorie deficit occurs when you burn more calories than you consume, says senior clinical dietitian Jessica Tilton. Here, she explains how physical activity and…
IMAGE study: Isatuximab plus pomalidomide and dexamethasone for RRMM in the real-world setting
Here we present a visual abstract of a retrospective study by Decaux et al. which evaluated real-world outcomes following at least one dose of Isa-Pd…
Study of Sacituzumab Govitecan Misses OS End Point in Pretreated Urothelial Carcinoma
The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients with pretreated advanced urothelial carcinoma.
Exploring a New Generation of Patient-Centric Cancer Clinical Trials
Register for Exploring a New Generation of Patient-Centric Cancer Clinical Trials, a virtual patient advocacy event hosted by the AACR.
Are we on track for diagnosing high‐grade urothelial carcinoma with a minimum quantity of five malignant cells in lower tract specimens? Critical analysis of The Paris System Quantitation Criteria
The Paris System for Reporting Urinary Cytology (TPS) requires at least 5–10 malignant cells to diagnose HGUC in lower and upper urinary tract specimens, respectively,…
A “Rock Star” in Patient-Reported Outcomes, Is Listening
Basch, an oncologist and researcher who moonlights as a bass player, is in tune with colleagues and patients.
Home | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Osimertinib With or Without Chemo is Top Choice for Frontline NSCLC
The NCCN guidelines have stated that osimertinib is the preferred category 1 treatment for patients with EGFR-mutated NSCLC discovered before the first line of therapy.
About
NCCN is a not-for-profit alliance of 33 leading cancer centers devoted to patient care, research, and education, is dedicated to improving and facilitating quality, effective,…
